NCT03951116 - Study of FCN-437c in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

December 8, 2021

Study Completion Date

December 8, 2021

Conditions

Solid Tumor, Adult

Interventions

DRUG

FCN-437

FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.

Trial Locations (3)

37203

Sarah Cannon Research Institute at Tennessee Oncology, Nashville

78229

South Texas Accelerated Research Therapeutics (START), San Antonio

91010

City of Hope National Medical Center, Duarte